Cancer vaccine to prevent glioblastoma recurrence
Part of Brain & nervous system, Cancer clinical trials.
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You had surgery to completely remove a glioblastoma in your brain's frontal, temporal, or occipital lobe, followed by radiation and/or chemotherapy
- Your MRI scan at 4 months after surgery showed no tumor recurrence
- Your overall health (measured by Karnofsky score) must be good enough to tolerate treatment
- Your blood counts, liver function, and kidney function must be normal or near-normal
- If you can become pregnant, you must use effective birth control during and for 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine made from your own immune cells (dendritic cells) to see if it can help control recurrent or progressive high-grade gliomas. It is for people whose brain tumor has returned after standard treatments.
This trial tests an experimental vaccine for glioblastoma, given after the usual radiation and chemotherapy (temozolomide). The goal is to see if the vaccine helps the immune system fight remaining cancer cells.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to treat glioblastoma that has come back after standard treatment. The vaccine is designed to help your immune system recognize and attack your tumor.
This trial tests a personalized vaccine made from your own immune cells to see if it can help treat glioblastoma. If you are currently getting standard treatments like surgery, chemo, and radiation, you may be able to join.
This trial tests whether adding a personalized vaccine made from your own immune cells and tumor can help standard chemotherapy and radiation work better against glioblastoma. It is for patients who have already had surgery and are starting or have just finished their first round of chemoradiation.
This trial tests a new vaccine (UCPVax) with or without pembrolizumab (an immunotherapy) given after standard radiation and chemotherapy for people with a specific type of glioblastoma (MGMT unmethylated). The goal is to see if adding these treatments can help prevent the cancer from coming back.
Hear when a new Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.